Rich Heyman, founder and executive chairman of the board of Metacrine
Rich Heyman-backed biotech gets out the axe as it sets course on survival mission
Back when Rich Heyman and the team at Metacrine floated their IPO in the fall of 2020, they breezed across the finish line into Nasdaq …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
